GlassScriptPhysician profile
Christa Filak
NPI 1811920911
$2,325.61
in general payments reported to CMS, 2019-2025
26 companies · $490 in 2025
The $490 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $323 · 2021: $187 · 2022: $223 · 2023: $174 · 2024: $354 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $451.37 | 2019-2025 | |
| Corium, LLC | $290.44 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $263.25 | 2019-2025 | Doc Band |
| Tris Pharma INC | $169.28 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $138.55 | 2024 | Qelbree |
| Merck Sharp & Dohme LLC | $134.41 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil |
| Incyte Corporation | $126.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.68 | 2020-2021 | |
| Glaxosmithkline, LLC. | $106.65 | 2021-2025 | Bexsero, Penmenvy |
| Sanofi Pasteur INC. | $88.30 | 2019-2025 | |
| Phadia US INC. | $64.11 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $51.39 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $35.59 | 2019-2023 | Crysvita |
| Shire North American Group INC | $34.60 | 2019 | |
| Mayne Pharma Commercial LLC | $32.97 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $25.80 | 2021 | |
| Kyowa Kirin, INC. | $23.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.39 | 2019 | |
| Cipher Pharmaceuticals US LLC | $21.88 | 2025 | Natroba, Spinosad |
| Noven Therapeutics, LLC | $21.29 | 2025 | Xelstrym |
| Aimmune Therapeutics, INC. | $20.58 | 2021 | |
| Pharming Healthcare, INC. | $17.36 | 2023 | Ruconest |
| Azurity Pharmaceuticals, INC. | $16.93 | 2025 | Alvesco |
| Ironshore Pharmaceuticals INC. | $15.90 | 2020 | |
| Inspire Medical Systems, INC. | $15.36 | 2023 | Inspire |
| Mission Pharmacal Company | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Filak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.